Ph 3 mBC clinical study This excerpt from today's SEC filings suggest that Ph 3 study is still planned but the expectation for start time is not mentioned. REOLYSIN Development for the Remainder of 2018 ...For the remainder of 2018, our clinical objective is to incorporate our immuno-oncology combination strategy that includes checkpoint inhibitors, targeted therapies and other anti-cancer agents as we finalize our registration strategy and clinical protocol in preparation for a phase 3 clinical study in mBC. We expect to enter into additional clinical collaborations examining potential biomarkers and commence enrollment in our combination studies with Keytruda in second line pancreatic cancer and multiple myeloma. Our expectation is that these combination studies will assist us in refining our phase 3 protocol for mBC and may also support further development around the innate and adaptive immunity components of the mechanism of action.